Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif  by Moretti, Sonia et al.
Biochimica et Biophysica Acta 1793 (2009) 1634–1645
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrInsights into the molecular function of the inactivating mutations of B-Raf involving
the DFG motif
Sonia Moretti a, Valentina De Falco d, Anna Tamburrino d, Flavia Barbi a, Maria Tavano a, Nicola Avenia b,
Fausto Santeusanio a, Massimo Santoro d, Antonio Macchiarulo c,⁎, Eﬁsio Puxeddu a,⁎
a Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
b Centro di Riferimento Regionale per l'Endocrinochirurgia, Università di Perugia, Perugia, Italy
c Dipartimento di Chimica e Tecnologia del Farmaco, Università di Perugia, Perugia, Italy
d Dipartimento di Biologia e Patologia Cellulare e Molecolare “L. Califano”, Università “Federico II”, Naples, Italy⁎ Corresponding authors. E. Puxeddu is to be contacte
Interna, Via E. dal Pozzo, 06126 Perugia, Italy. Tel.: +3
5730855. A. Macchiarulo, Dipartimento di Chimica e Te
Liceo 1, 06123 Perugia, Italy. Tel.: +39 075 5855114; fa
E-mail addresses: antonio@chimfarm.unipg.it (A. Ma
eﬁsio.puxeddu@unipg.it (E. Puxeddu).
0167-4889/$ – see front matter © 2009 Elsevier B.V. A
doi:10.1016/j.bbamcr.2009.09.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 November 2008
Received in revised form 28 August 2009
Accepted 1 September 2009
Available online 6 September 2009
Keywords:
BRAF mutation
B-RafV600E
B-RafD594V
B-RafG596R
Kinase activity
Molecular dynamics simulationBRAF gene mutations have been associated with human cancers. Among the naturally occurring mutations,
two that involve amino acids of the conserved DFG motif in the activation loop (D594V and G596R), appear
to be inactivating. Aim of this study was to analyze the molecular mechanisms involved in the loss of
function of B-Raf inactivating mutation G596R. Furthermore, the ability of the B-Raf DFG motif mutants to
generate heterodimers with C-Raf and the possible functional consequences of the B-Raf/C-Raf heterodimer
formation was examined. Wet molecular experiments in HEK293T cells demonstrate that B-RafG596R is a
kinase-impaired mutant. Molecular dynamics simulations show that the loss of function of B-RafG596R
depends on a restraining effect of Arg596 on the catalytic residue Asp594, which results in the loss of the
appropriate spatial localization and/or conformation of the latter necessary for anchoring ATP to the enzyme.
Exploration of B-Raf/C-Raf heterodimer formation indicates the occurrence of functioning heterodimers in
the case of all the DFG B-Raf mutants, independently from the expected differences in spatial conformation
of the activation loop, although the transforming activity of the mutants appear negligible. In conclusion, this
study delivers novel information on the functional properties of the B-Raf DFG motif inactivating mutants
and on the mechanisms driving B-Raf/C-Raf heterodimerization and consequent C-Raf transactivation.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The activation of Ras–Raf–Mek–Erk pathway in response to
extracellular signals, plays a pivotal role in the regulation of cell
proliferation, survival, and senescence [1,2]. While Ras is a small G
protein that is anchored to the inner part of the cell membrane, Raf,
Mek, and Erk are cytosolic protein kinases whose sequential
activation by each other, leads to a three-tiered signaling cascade.
In particular, three Raf isoforms are known in mammals: A-Raf, B-
Raf, and C-Raf, with BRAF being frequently mutated in cancer (see
below).
The kinase activity of B-Raf is regulated by an equilibrium between
the inactive and active conformations of the enzyme that show
different substrate accessibility to the catalytic site. In particular, the
inactive conformation of B-Raf is endowed by a closed conformationd at Dipartimento di Medicina
9 075 5783406; fax: +39 075
cnologia del Farmaco, Via del
x: +39 075 5855114.
cchiarulo),
ll rights reserved.of the activation loop (residues Asp593-Glu622 of the C-terminal
lobe) which prevents the access of the substrate to the catalytic site.
Conversely, the active conformation of B-Raf is characterized by an
open conformation of the activation loop that makes the catalytic cleft
accessible to the substrate. The crystal structures of B-Raf in the
inactive [3] and active [4] conformations support the notion that the
shift of the activation loop between a closed and open state is the only
event needed to activate the enzyme. Under basal conditions,
stabilizing interactions between the activation loop and the glycine-
rich loop of the N-terminal lobe favor the inactive state of the enzyme.
Upon the occurrence of post-translational modiﬁcations and/or point
mutations, unfavorable interactions of these regions promote a
conformational transition of B-Raf to the catalytically active form [3].
BRAF gene is mutated in approximately 7% of human cancers [5].
Among these, melanoma and papillary thyroid carcinoma (PTC) show
the highest rate of BRAF mutations [6,7]. The majority of point
mutations so far identiﬁed, is localized in the glycine-rich loop and the
activation loop [3,8]. Although the most common mutations of B-Raf
activate the enzyme, such as the frequent replacement of a glutamic
acid for valine at position 600 (B-RafV600E), at least ﬁve other cancer-
associatedmutants (B-RafG466E, B-RafG466V, B-RafG474R, B-RafD594V, and
B-RafG596R) show an impaired B-Raf kinase activity in vitro [3,9–12].
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proximity, respectively, whereas D594 and G596 are located in the
activation segment of B-Raf where they form the kinase conserved
DFG motif (residues 594–596). While it is likely that all these
mutations affect the conformational equilibrium of the enzyme
between the inactive and catalytically active forms, a clear explana-
tion of the inactivity was provided only for B-RafD594V, with the
mechanism being ascribed to the key role that the kinase-conserved
aspartate plays in chelating themagnesium atom that anchors the ATP
to the enzyme [13,14].
Interestingly, although all these mutants appear kinase impaired
for three of them (B-RafG466E, B-RafG466V, and B-RafG596R) evidence is
provided for their ability to activate to some extent Mek and Erk, due
to their capacity to heterodimerize with C-Raf and to induce its
transactivation [3,15]. More recent data suggest that B-Raf/C-Raf
heterodimerization, either involving B-RafWT or B-Raf inactivating
mutants, occurs as part of the physiological activation process and
that the heterodimer has distinct biochemical properties that may be
important for the regulation of some biological processes [16].
Mutational experiments and peptide arrays provided evidence for
the existence of molecular regions in the kinase domains of both C-Raf
and B-Raf responsible for high- and medium-afﬁnity heterodimeriza-
tion [16].
In order to shed further light on the function and on the potential
transforming properties of B-Raf inactivatingmutants, in this workwe
investigate B-RafG596R and B-RafD594V using in silico molecular
dynamics, and a number of in vitro and in vivo experimental studies.
2. Materials and methods
2.1. Plasmids
pEFP vector-expressing myc-tagged B-RafWT and B-RafV600E were
kindly provided by Dr. Jeffrey A. Knauf (MSKCC, New York City, USA).
pEFP vector-expressingmyc-tagged B-RafV599Ins, B-RafD594V, B-RafG596R,
B-RafG596E, B-RafD594V+V600E, B-RafG596R+V600E, B-RafG596E+V600E, and
B-RafK483M were obtained from pEFP-BRAFWT or pEFP-BRAFV600E, as
appropriate, by site-directed mutagenesis, using the QuickChange XL
mutagenesis kit (Stratagene, La Jolla, CA, USA), according to manufac-
turer's instructions.
pEGFP-C1 vector-expressing GFP-tagged B-RafV600E, B-RafG596R
and B-RafG596R+V600E were obtained by insertional cloning of PCR-
generated full length cDNA of the BRAF mutants.
pEFP vector-containing myc-tagged C-Raf was kindly provided by
Dr. Christopher J. Marshall (Cancer Research UK Centre for Cell and
Molecular Biology, London, UK).
2.2. Cell cultures
HEK293T and COS-7 cells were from American Type Culture
Collection (ATCC, Manassas, VA, USA) and were grown in Dulbecco's
Modiﬁed EagleMedium (DMEM) supplementedwith 10% fetal bovine
serum (GIBCO, Paisley, PA, USA).
NIH-3T3 cells were from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were grown in DMEM supplemented with
10% calf serum (CS) (HyClone, Logan, UT, USA).
Transient transfections were carried out with the ExGene 500
reagent according to manufacturer's instructions (Fermentas, Bur-
lington, ON, Canada). Cells were seeded at a density of 1.5×106/
100mmdish the day before transfection, transfectedwith 2 μg of DNA
and harvested 48 h later.
Stable transfections of NIH-3T3 cells were carried out with the
lipofectamine 2000 reagent according to manufacturer's instructions
(Invitrogen, Carlsbad, CA, USA). In detail, cells were seeded at a
density of 1.5×106/100 mm dish the day before transfection,
transfected with 5 μg of the GFP-tagged B-Raf expression constructs,divided 1:5 24 h later and put into selection medium (DMEM with
10% calf serum and 800 μg/ml of G418 (Gibco, Paisley, PA, USA)) 48 h
after transfection. The selection was prolonged for 10 days and then
the cells were assayed for transgene expression by Western blotting
using an anti-GFP antibody (Sigma, St. Louis, MI, USA).
2.3. Kinase assays
For the B-Raf kinase assays, transiently transfected HEK293T cells
were cultured for 30 h in complete medium, and then kept for 18 h in
serum-deprived medium before harvesting. In detail, cells were lysed
in a buffer containing 50 mM N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES; pH 7.5), 1% (vol/vol) Triton X-100,
50 mMNaCl, 5 mM ethylene glycol-bis(b -amino-ethyl ether) N, N, N',
N' tetraacetic acid (EGTA), 50 mM NaF, 20 mM sodium pyrophos-
phate, 1 mM sodium vanadate, 2 mM phenylmethylsulphonyl
ﬂuoride, 0.2 mg each of aprotinin and leupeptin per ml. Lysates
were clariﬁed by centrifugation at 10,000×g for 15 min and the
supernatant processed. B-Raf kinase was immunoprecipitated with
the anti-myc tag (9E10) antibody (Santa Cruz, CA, USA) and
resuspended in a kinase buffer containing 25 mM sodium pyrophos-
phate, 0.02–3 mM ATP and 1 μg of recombinant GST-Mek (Upstate
Biotechnology Inc., Lake Placid, NY, USA). After 15 min incubation at
30 °C, reactions were stopped by adding 2×Laemmli buffer. Proteins
were then subjected to 10% SDS gel electrophoresis. The degree of
Mek phosphorylationwas analyzed byWestern Blotting using an anti-
phospho Mek1/2 (MAP kinases 1 and 2) antibody (#9121) (Cell
Signaling, Beverly, MA, USA).
In order to ﬁnd the more efﬁcient kinase assay conditions, in vitro
pMEK assays of B-RafWT and B-RafV600E were repeated in the presence
of three increasing concentrations of ATP (0.02, 0.8 and 3 mM), and
the best condition was chosen for the further tests.
2.4. Immunoblotting experiments
Immunoblotting experiments were performed according to stan-
dard procedures. Anti-phospho p44/42 MAPK (#9102), speciﬁc for
MAPK (Erk1/2) phosphorylated at Thr202/Tyr204, anti-phospho
Mek1/2 (MAP kinases 1 and 2) (#9121), speciﬁc for Mek1 and
Mek2 phosphorylated at Ser217/Ser221, and anti-Mek1/2 (#9122)
were purchased from Cell Signaling (Beverly, MA, USA). Anti-myc tag
(9E10) antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Secondary antibodies coupled to horseradish
peroxidase were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA).
2.5. Reporter assays
For reporter assays HEK293T cells were co-transfected with B-Raf
expressing vectors and 0.1 μg of the pdAP1-luc reporter (containing
the luciferase (Fireﬂy luciferase) reporter gene driven by a basic
promoter element (TATA box) joined to tandem repeats of AP1
binding elements [17]) and 0.01 μg of phRL, which expresses Renilla
luciferase from Renilla reniformis for normalization. The total amount
of plasmid DNA was adjusted with pcDNA3-β-Galactosidase. Fireﬂy
and Renilla luciferase activities were assayed using the Dual-
Luciferase Reporter System (Promega Corporation, Madison, WI,
USA). Light emission was quantiﬁed using a Berthold Technologies
luminometer (Centro LB 960). Experiments were performed in
triplicate and data were represented as average±S.D.
2.6. Molecular dynamics simulations
The atomic coordinates of B-RafWT and B-RafV600E were retrieved
from the protein data bank (pdb codes: 1uwh, 1uwj) and the inhibitor
BAY43-9006 was removed while keeping the crystal water [18].
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Diego, CA). The region encompassing residues 601–612 (12 residues),
not solved into the crystal structures, was modeled using the loop
building routine of Modeller [19]. B-RafD594V and B-RafG596R were
generated replacing Asp594 and Gly596 respectively with valine and
arginine residues in the structure of 1uwh, while B-RafD594V+V600E
and B-RafG596R+V600E were generated performing the same replace-
ments in the structure of 1uwj. A similar strategywas used to generate
the insertion of valine between positions 598–599, as previously
described [20]. The resulting loop regions of each model were energy
reﬁned using 1000 steps of conjugate gradients minimization in order
to remove bad contacts. At this purpose, Charmm22 force ﬁeld was
used [21].
Each model was solvated using Solvate v.1.0 with its default
settings (Solvate v1.0 is written by Helmut Grubmüller, Theoretical
Biophysics Group, Institut für Medizinische Optik, Ludwig-Maximi-
lians-Universität München, München, Germany). Sodium and chlo-
rine atoms were also placed to counter-balance the net charges of the
enzyme. All water molecules within 1.5 Å of any protein atom were
then removed with the exception of the crystal water. After the
construction of the solvent environment, each system was composed
by about 35000 atoms.
All the models were energy minimized for 5000 steps using the
method of conjugate gradients as implemented in NAMD v.2.5 [22].
During the minimization protocol, the backbone of the enzyme was
kept ﬁxed. The water shell and all counter-ions were then equilibrat-
ed for 500 ps at 300°K. The temperature of 300°K was gradually
reached starting from 0°K in the ﬁrst 10 ps of the simulation. The ﬁnal
coordinates and velocities of the resulting systems were submitted to
a productive simulation of 4 ns where the constrains on the backbone
atoms were removed. The atomic coordinates of each system were
saved every 10 ps.
Spherical harmonic boundary conditions (SBC) were applied in all
the simulations. SBC consists in applying a potential with a force
constant of 0.1 kcal/mol ⁎ Å2 that increases exponentially by two folds
on the solvent atoms that reach a distance of 45 Å from the centre of
mass of the solute. During all the simulations, a time step of 2 fs was
used and the ShakeH algorithmwas applied to all hydrogen atoms; 1–
4 interactions were not scaled whereas all 1–3 pairs were excluded
from the non-bonded interactions; smoothing functions were applied
to both the electrostatic and van derWaals forces on the range from 8
to 12 . Molecular dynamic calculations were performed using NAMD
v.2.5 and Charmm22 force ﬁeld.
2.7. BRAF and CRAF co-transfection and immunoprecipitation
experiments
Transient transfections were carried out with the ExGene 500
reagent according to manufacturer's instructions (Fermentas, Bur-Fig. 1. Functional analysis of B-Raf mutants in HEK293T cells. (A) Search of the best conditi
HEK293T cells expressing B-RafWT and B-RafV600E constructs were kept in serum-deprived m
anti-myc and subjected to kinase assays with recombinant GST-Mek in the presence o
phosphorylation between B-RafV600E and B-RafWT is indicated for each assay as V600E/wt ra
transfected HEK293T cells and HEK293T cells expressing B-RafV600E, B-RafD594V and B-RafK-
(800 μg) were immunoprecipitated with anti-myc and subjected to kinase assay with recom
levels based on the transgene expression. (C) In vitroMek phosphorylation assays of the ent
Raf mutants were kept in serum-deprived medium (18 h) and harvested. Protein lysates (8
recombinant GST-Mek in the presence of 3 mM ATP. (D) Statistical analysis of the kinase
arbitrary units obtained from the pMEK band densitometry. B-Raf activating mutants show
showed a very signiﬁcantly higher kinase activity than the mutants harboring inactivating su
RafWT vs. B-RafG596R+V600E P=0.0007). (E) Effects exerted by B-Raf mutants on B-Raf-media
expressing the indicated B-Raf mutants were kept in serum-deprived medium (18 h)
phosphospeciﬁc antibodies. Total amounts ofMek are shown for normalization. Data are repr
transfected with BRAF mutants and the “activator protein 1 (AP-1) luciferase reporter gen
transfected construct was normalized in the case of the D594 mutants according to their low
assays±SDwere expressed as fold increase compared to background (Lower panel). Reporte
B-RafWT (P=0.0004) and for all the functioning B-Raf isoforms compared to single inactivatin
(Pb0.0001). (pEF: mock-transfected cells).lington, ON, Canada). In detail, cells were seeded at a density of
6×105/60 mm dish the day before transfection, transfected with
1.2 μg of the myc-tagged B-Raf expressing vectors and 0.8 μg of the
myc-tagged C-Raf expressing construct. The cells were cultured for
30 h in complete medium and then kept for 18 h in serum-deprived
medium before harvesting.
Molecular complexes assembled with B-Raf were immunopreci-
pitated using an anti-B-Raf antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and resuspended in 2× Laemmli buffer. Immunopre-
cipitates were then subjected to 10% SDS gel electrophoresis. The
presence of B-Raf and C-Raf was searched by western blotting using
an anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), able to detect the tags of both proteins, and an anti-C-Raf
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), speciﬁc for
C-Raf.
B-Raf and C-Raf expression and the degree of MAPK phosphory-
lation were evaluated by Western Blot on protein extracts using an
anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and the anti-phospho p44/42MAPK (#9102) (Cell Signalling, Beverly,
MA, USA), respectively, according to standard procedures.
2.8. Focus assays
For focus assays, NIH-3T3 cells were seeded at a density of 1.3×105
cells/100 mm dish the day before the transfection, transfected with
5 μg of DNA by CaCl2 precipitation, shifted to 5% CS DMEM 24 h later,
and left at conﬂuence for 15 days with medium changes every 3 days.
Fifteen days after transfection, the plates were ﬁxed and colored
with crystal violet, and density of transformation foci compared.
Experiments were performed in duplicate and data were collected
from three independent runs. Foci counts were represented as
average±S.D.
2.9. In vivo tumorigenesis experiments in NOD-SCID mice
One million of NIH-3T3 cells stable transfected with BRAF
mutants was injected subcutaneously in the right ﬂank of 6
weeks-old female NOD-SCID immune-suppressed mice. Every
4 days the transplanted animals were inspected and if a subcuta-
neous nodule could be detected, its volume was evaluated applying
the rotational ellipsoid formula (V=AxB2/2; A=axial diameter;
B=rotational diameter). Twenty days after injection, the mice were
sacriﬁced. Experiments were performed in triplicate and repeated in
three independent runs.
2.10. Statistical analysis
For the comparison of the kinase assay results of the different B-Raf
mutants, the free downloadable ImageJ software, version 1.43ons for the in vitro Mek phosphorylation assays. Vector-transfected HEK293T cells and
edium (18 h) and harvested. Protein lysates (800 μg) were immunoprecipitated with
f three different ATP concentrations (0.02, 0.8 and 3 mM). Fold difference of Mek
tio. (B) Comparison of the kinase activity of the B-RafD594V and B-RafK- mutants. Vector-
constructs were kept in serum-deprived medium (18 h) and harvested. Protein lysates
binant GST-Mek in the presence of 3 mM ATP after normalization of the B-Raf protein
ire B-Raf mutants panel (Representative gel). HEK293T cells expressing the indicated B-
00 μg) were immunoprecipitated with anti-myc and subjected to a kinase assay with
assays. Average results of three independent experiments±SD were expressed using
ed a signiﬁcantly higher kinase activity than B-RafWT (P=0.04). Conversely, B-RafWT
bstitutions (B-RafWT vs. D594 mutants Pb0.0001; B-RafWT vs. B-RafG596R P=0.0006; B-
ted stimulation of the mitogen-activated protein kinase (MAPK) cascade. HEK293T cells
and harvested. Total cell lysates (50 μg) were immunoblotted with the indicated
esentative of three different experiments. (F) Reporter assays. HEK293T cells transiently
e (AP1-Luc)” were kept in serum-deprived medium (18 h) and harvested. Amount of
er expression efﬁciency (Upper panel). Average results of three independent Luciferase
r gene activation resulted signiﬁcantly higher for B-Raf activating mutants compared to
gmutants (D594V orG596R) or the B-Raf V600E doublemutants (+D594V or+G596R)
1637S. Moretti et al. / Biochimica et Biophysica Acta 1793 (2009) 1634–1645(http://rsbweb.nih.gov/ij/index.h), was used for quantiﬁcation of
the pMEK band density. The two-tailed unpaired Student's t test
was used for statistical analysis either of the kinase assays or of the
luciferase assays data or of the transformation assay data. All P
values were two sided and differences were signiﬁcant when
Pb0.05 (Graph Pad InStat software program, version 3.06.3, San
Diego, CA).3. Results
3.1. The G596R amino acid substitution impairs B-Raf kinase and exerts
an inactivating effect on the B-RafV600E activating mutant
In order to compare the effect of B-Raf G596R and D594V
mutations, and to evaluate their inﬂuence on the strong activating
1638 S. Moretti et al. / Biochimica et Biophysica Acta 1793 (2009) 1634–1645V600Emutation, the enzymatic action of B-Raf mutantswas evaluated
by in vitro biochemical assays. We generated the single B-RafG596R and
B-RafD594V (inactivating) and B-RafV599Ins and B-RafV600E (activating)
mutants as well as double mutants in which G596R and D594V
mutations were inserted in cis in the background of a B-RafV600E
mutant. The various constructs were expressed in HEK293T cells.
Intrinsic kinase activity of the B-Raf mutants was measured by an in
vitro kinase assay using Mek as a substrate; signaling in intact cells
was measured by immunoblot with pMek and pMAPK speciﬁc
antibodies and studying the degree of activation of a reporter gene
of the MAPK pathway.
In ﬁrst instance, we searched the best conditions for the in vitro
pMEK assays testing three different ATP concentrations (0.02, 0.8 and
3 mM) in the reaction mixture. As shown in Fig. 1A, the 3 mM ATP
concentration is the ATP concentration that allows the best differen-
tiation of the kinase activity of B-RafWT and of the high kinase
activating mutant B-RafV600E. Thus, 3 mM ATP was the condition
chosen for the accomplishment of the assays. Furthermore, we
conﬁrmed with our in vitro pMEK assay the negligible kinase activity
of the known kinase-dead B-RafK483M mutant (also known as B-RafK-
and so called from here on) and of B-RafD594V (Fig. 1B). The
simultaneous analysis of the entire B-Raf mutant panel highlights
that, as expected, B-RafV599Ins and B-RafV600E (activating) mutations
signiﬁcantly potentiate Mek phosphorylating ability of B-Raf with
respect to the wild type control. At variance, the B-RafG596R and B-
RafD594V (inactivating) mutations impair signiﬁcantly this activity,
with the retention of a minimal activity in the case of the former
(about 20% of that of B-RafWT) andwith its complete loss in the case of
the latter. Importantly, B-RafG596R and B-RafD594V suppress signiﬁ-
cantly the kinase function of B-RafV600E in the doublemutants to levels
observed in the corresponding single mutant (Fig. 1C). As far as the
possibility that endogenous B-Raf or C-Raf may precipitate with the
anti-myc antibody interfering with the kinase assay performance, Fig.
1C shows that no endogenous B-Raf can be detected in the anti-myc IP
of vector-transfected HEK293T cells (ﬁrst lane on the left). We did a
similar control for C-Raf and could not detect any C-Raf in the anti-
myc immunoprecipitate, as well (data not shown).
B-Raf-mediated stimulation of the mitogen-activated protein
kinase (MAPK) cascade (Mek and Erk) in HEK293T cells transiently
transfectedwith the various B-Raf expressing constructs yields results
that are similar to those of the kinase assays. Phosphorylation of Mek
and MAPK is signiﬁcantly reduced in cells transfected with B-RafG596R
and B-RafD594V, with respect to wild type B-Raf and does not recover
in those transfected with the double mutants B-RafG596R+V600E and B-
RafD594V+V600E (Fig. 1E). However, it should be noted that in the
integral cell the G596R mutants are completely inactive as the D594V
ones.
In agreement with the previous experiment, reporter assays in
HEK293T cells co-transfected with the “activator protein 1 (AP-1)
luciferase reporter gene (AP1-Luc)”, a known target of the MAPK
cascade, show that AP-1 luciferase induction is negligible in the cells
transfected with the single mutants B-RafG596R and B-RafD594V and
does not recover in those transfected with the double mutants B-
RafG596R+V600E and B-RafD594V+V600E. On the contrary, AP-1 lucifer-Table 1
Averages and standard deviations of van der Waals interaction energies between the activa
Mutant 0–1 ns 1–2 ns
vdW (kcal/mol) vdW (kca
B-RafWT a −33.90±3.86 −34.75±
B-RafV600E a −25.23±5.32 −22.14±
B-RafD594V −34.06±4.08 −28.50±
B-RafG596R −26.80±3.76 −26.13±
B-RafD594V+V600E −28.59±5.82 −24.40±
B-RafG596R+V600E −32.31±4.58 −33.13±
a Data are from ref. [20].ase is signiﬁcantly induced in the cells expressing the activating
mutants compared not only to those expressing the inactivating
mutants but also B-RafWT (Fig. 1F).
In order to demonstrate the repeatability of the ﬁndings also in
other cell lines, we repeated the transient expression experiments
either in COS-7 cells or in NIH-3T3 cells. At variance with the data
obtained in HEK293T cells, all the studied inactivating mutants (B-
RafG596R, B-RafG596R+V600E, B-RafD594V and B-RafD594V+V600E) elicited
some degree of activation of the MAPK pathway in COS-7 (Supple-
mentary Fig. 1) and NIH-3T3 cells (Supplementary Fig. 2). These
ﬁndings, which conﬁrm data from previous studies [3], indicate the
occurrence in COS-7 and NIH-3T3 cells of molecular interactions,
involving the inactivating B-Raf mutants and other intra-cellular
molecules, which rescue at least in part their signaling capacity in the
intact cell. Very recently, B-Raf/C-Raf heterodimerization and result-
ing C-Raf transactivation was recognized as the mechanism which
supports this phenomenon [3,15,16].
In summary, the experiments in HEK293T cells indicate that the
G596R amino acid substitutions impairs B-Raf kinase and exerts an
inactivating effect on the B-RafV600E mutant in manners that are
similar to that observed for the D594V and the K483M (K-)
substitutions, although it maintains a minimal in vitro pMEK kinase
activity in the presence of high ATP concentration. The impairment of
the kinase function in the mutants containing simultaneously the DFG
motif mutations and the V600E substitution underscores the critical
role of the DFG motif for the catalytic function of the enzyme.
Interestingly, the presented data suggest also a cell line-speciﬁc
partial rescue of the signaling capacity of the inactivating mutants in
COS-7 and NIH-3T3 intact cells (not in cell extracts) due to the
interaction of the impaired kinases with another intra-cellular
mediator which may be hypothesized to be C-Raf in accordance
with previous data from the literature.
3.2. Molecular dynamics simulations conﬁrm the importance of the DFG
motif in BRAF catalytic activation
Molecular dynamics simulations were performed on the structural
models of the mutants to investigate the inﬂuence of inactivating
mutations, alone or combined with the activating mutations, on the
inactive conformation of B-Raf. We calculated the average van der
Waals (Table 1) and electrostatic (Table 2) interaction energies
between the activation loop (residues 594–623) and the catalytic site
along the molecular dynamics simulations. In particular, the catalytic
site was deﬁned with those residues belonging to the glycine-rich
loop (residues 463–472) and C helix (residues 493–507). These
interaction energies were compared with those obtained in our
previously reported simulations of B-RafWT and B-RafV600E [20].
In ﬁrst instance, these computational experiments show that both
single inactivating mutants (B-RafD594V and B-RafG596R) stabilize the
inactive conformation of the enzyme by lowering the electrostatic
energy of interaction (Table 2, Fig. 2). Conversely, the activatingmutant
B-RafV600E destabilizes the inactive conformation of the enzyme with
the substitution of Val600 to glutamic acid not only causing the loss of
the hydrophobic interaction in favor of electrostatic repulsions, astion loop and the catalytic site of B-Raf calculated during each ns of the simulations.
2–3 ns 3–4 ns
l/mol) vdW (kcal/mol) vdW (kcal/mol)
2.45 −31.10±2.86 −26.95±4.64
3.20 −22.27±3.18 −21.77±3.93
4.83 −24.29±3.90 −17.27±3.54
4.59 −18.38±2.94 −15.52±2.35
4.81 −24.80±3.07 −26.19±3.43
4.04 −28.13±3.38 −27.67±1.62
Table 2
Averages and standard deviations of electrostatic interaction energies between the activation loop and the catalytic site of B-Raf calculated during each ns of the simulations.
Mutant 0–1 ns 1–2 ns 2–3 ns 3–4 ns
Elect.(kcal/mol) Elect.(kcal/mol) Elect.(kcal/mol) Elect.(kcal/mol)
B-RafWT a −68.04±13.94 −57.16±12.44 −60.69±17.48 −79.29±24.37
B-RafV600E a −60.45±17.51 −42.87±27.74 −2.96±18.06 −14.04±29.53
B-RafD594V −102.60±13.21 −105.56±14.34 −89.32±15.41 −71.13±12.97
B-RafG596R −62.86±14.53 −65.76±14.18 −69.21±25.90 −111.39±7.41
B-RafD594V+V600E −63.88±40.41 −101.12±33.17 −112.65±9.01 −144.89±14.90
B-RafG596R+V600E −77.37±18.85 −76.09±20.07 −89.99±9.31 −62.71±21.65
a Data are from ref. [20].
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side chains of glutamic acid and Phe468 of the glycine rich loop. This is
particularly evidenced along the entire simulation by the less favorable
vdW interaction between the activation loop and the catalytic site of B-
RafV600E with respect to the wild type enzyme (Table 1).
At variance, the analysis of B-RafD594V+V600E and B-RafG596R+V600E
simulations indicates that the double mutants have different
behaviors with the introduction of D594V in the V600E mutant
contributing to the stabilization of the inactive conformation (Fig. 2A),
while the introduction of G596R, on the opposite, destabilizing such
conformation of B-Raf (Fig. 2B). While this latter observation may be
interpreted as the net result of attracting and repulsive electrostatic
energies ensuing the introduction of positively charged and nega-
tively charged residues in the activation loop, the former observationFig. 2. Comparison of the electrostatic energies of interaction between the activation loop
activating mutation B-RafV600E, inactivating mutation B-RafD594V and double mutation B-RafD
B-RafV600E, inactivating mutation B-RafG596R and double mutation B-RafG596R+V600E.is more challenging to explain. One hypothesis rises from the
inspection of the conformational movements of Val594 and Glu600
along the simulation (Fig. 3). Val594 is an hydrophobic residue that is
largely exposed to the solvent. During the central part of the
simulation (ns 1.5-3, Fig. 2A), as far as it tries to minimize the polar
contacts increasing the hydrophobic ones, Val594 promotes a sort of
hydrophobic collapse of the activation loop which involves Leu597. It
ensues an initial stabilization of the inactive conformation of the
enzyme that is similar to that observed in the single D594V mutant.
Around 3 ns of the simulation, this cluster of hydrophobic residues
induces a particular conformation of the activation loop where the
presence of Glu600 favors the formation of a salt bridge with the side
chain of Arg603 (Fig. 3). This latter event is responsible of the strong
stabilization observed during the last nanosecond of the simulationand the catalytic site of B-Raf. (A) Electrostatic energies of interaction of B-RafWT, the
594V+V600E. (B) Electrostatic energies of interaction of B-RafWT, the activating mutation
Fig. 3. Superposition of the atomic coordinates of B-RafD594V+V600E at the beginning of
the simulation and at the end of the simulation showing the starting (green sticks) and
ﬁnal (magenta sticks) conformations of Val594 and Glu600. Root mean square
deviations (RMSD, Å) of the conformational movements are reported in bracket.
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in the inactive conformation, can occur only when both D594V and
V600E mutations are concomitantly present on the activation loop.Fig. 4. (A) Occupancy of hydrogen bond interactions between the side chain of Arg596 and
the atomic coordinates of B-RafG596R at the beginning of the simulation and at the end of the
of Arg596 and Asp594. Root mean square deviations (RMSD, Å) of the conformational m
RafG596R+V600E at the beginning of the simulation and at the end of the simulation showing
and Glu600. Root mean square deviations (RMSD, Å) of the conformational movements arHowever, the hydrophobic collapse of the activation loop should
only marginally explain the inactivity of B-RafD594V+V600E mutant
since also B-RafD594V, though lacking this conformational event, acts
as kinase-dead mutant in the assays. Thus, the molecular basis of the
inactivity of B-RafD594V and B-RafD594V+V600E mutants is mainly
ascribed to the lone pair of electrons of the aspartate chelating the
magnesium [13,14] that is lost in the D594V substitution.
As far as G596R mutants are concerned (B-RafG596R and
B-RafG596R+V600E), the analysis of the interactions involving Arg596
unveils that this residue is increasingly implicated in the formation
of electrostatic enforced hydrogen bonds with the catalytically
important residue Asp594 during the entire course of the simula-
tion. In particular, the occupancy of the hydrogen bonds existing
between Arg596 and Asp594 along the time of the simulation, rises
from the 8% of the ﬁrst nanosecond to the 60% during the last
nanosecond in B-RafG596R and from the 7% to more than 90% in B-
RafG596R+V600E (Fig. 4). Thus, the presence of such interaction is
independent from the introduction of V600E mutation in the enzyme
and contributes to the stabilization of the inactive conformation of B-
Raf. More importantly, taking into account that Asp594 is involved in
the catalytic mechanism of B-Raf by providing the anchoring point of
the magnesium atom to the catalytic site [13,14], the salt bridge
interaction between Arg596 and Asp594 may provide an interesting
explanation to the inactivity of B-RafG596R and B-RafG596R+V600E
mutants. In particular, Arg596 may take away Asp594 from chelatingAsp594 in B-RafG596R (white bar) and B-RafG596R+V600E (blue bar). (B) Superposition of
simulation showing the starting (green sticks) and ﬁnal (magenta sticks) conformations
ovements are reported in bracket. (C) Superposition of the atomic coordinates of B-
the starting (green sticks) and ﬁnal (magenta sticks) conformations of Arg596, Asp594
e reported in bracket.
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salt bridge.
In order to conﬁrm this hypothesis, we prepared the B-RafG596E
and B-RafG596E+V600E mutants, characterized by the substitution of
Gly596with a glutamate residue, which has a side chain of similar sizeas arginine, but cannot form the proposed salt-bridge with Asp594. As
shown in Fig. 5, at variance with B-RafG596R and B-RafG596R+V600E, the
mutants containing the G596E substitution show a kinase activity
super imposable to that of B-RafV600E and signiﬁcantly higher than
B-RafWT either in the kinase assays (Fig. 5A and B) or in the MAPK
cascade activation studies in HEK293T cells (Fig. 5C). All together,
these ﬁndings conﬁrm that the sequestration of Asp594 from its
magnesium binding function is an essential determinant of the loss
of activity of the G596R mutant.
In summary, our data indicate that, although both B-RafD594V and
B-RafG596R stabilize the inactive conformation of the enzyme by
lowering the electrostatic energy of interaction, it is unlikely that this
is the origin of the impaired catalytic activity of the enzyme. A support
to this notion comes from the observation that the engineered double
mutants (B-RafG596R+V600E and B-RafD594V+V600E) affect in a opposite
manner the stability of the inactive conformation of B-Raf, but always
act as kinase-impaired mutants in the kinase assays.
While the origin of the inactivity of B-RafD594V and B-RafD594V+V600E
mutants can be ascribed to thedisruptionof themagnesiumbinding site
ensuing the D594V substitution and the loss of the lone pair of electrons
of the side chain, more intriguing appears the reason of the inactivity of
B-RafG596R and B-RafG596R+V600E mutants.
By analyzing the interaction patterns of Arg596 in the simulations of
B-RafG596R andB-RafG596R+V600E, thehypothesis raises that the impaired
activity of G596R mutants relies on an indirect effect of Arg596 on the
magnesium binding site that occurs through the formation of a salt
bridge with the side chain of Asp594. Creation and activity proﬁling of
G596E mutants has allowed to conﬁrm this hypothesis.
3.3. B-Raf mutants heterodimerization with C-Raf
In order to conﬁrm the ability of the studied B-Raf mutants to
form functioning heterodimers with C-Raf and to evaluate the effect
of the different molecular dynamics simulations-detected A-loop
conformational changes on B-Raf/C-Raf heterodimerization and C-Raf
transactivation, we co-transfected transiently a C-Raf construct with
the B-Raf mutants in HEK293T cells and evaluated the formation of
B-Raf/C-Raf heterodimers searching C-Raf in B-Raf immunoprecipi-
tates. Moreover, the activation of the MAPK pathway was assessed by
the quantiﬁcation of phospho-Erk. The detection of clearlymeasurable
amounts of C-Raf in B-Raf immunoprecipitates indicates the formation
of B-Raf/C-Raf heterodimers in the case of all the B-Raf isoforms
considered, includingB-RafWT, the singlemutants B-RafV600E, B-RafD594V,
B-RafG596R and B-RafK- and the double mutants B-RafD594V+V600E and B-
RafG596R+V600E (Fig. 6A). As far as the possibility that endogenous or
transfected C-Raf may precipitate with the anti-B-Raf antibody, Fig. 6A
shows that no endogenous or exogenous C-Raf could be detected in the
anti-B-Raf IP of vector-transfected HEK293T cells or of vector-trans-
fected HEK293T cells over-expressing C-Raf (ﬁrst and second lane).
Moreover, as shown in Fig. 6B, whereas C-Raf or inactive B-Raf mutants
alone do not stimulate Erk phosphorylation in HEK293T cells, co-
expression of C-Raf with the single mutants B-RafK-, B-RafD594V and B-Fig. 5. Analysis of functional activity of B-RafG596E and B-RafG596E+V600E mutants. (A) In
vitro MEK phosphorylation assays (Representative gel). HEK293T cells expressing the
indicated B-Raf mutants were kept in serum-deprived medium (18 h) and harvested.
Protein lysates (800 μg) were immunoprecipitated with anti-myc and subjected to a
kinase assay with recombinant GST-Mek in the presence of 3 mM ATP. (B) Statistical
analysis of the kinase assays. Average results of three independent experiments±SD
were expressed using arbitrary units obtained from the pMEK band densitometry. B-
RafG596E and B-RafG596E+V600E mutants showed a signiﬁcantly higher kinase activity
than B-RafWT (respectively P=0.01 and P=0.008), comparable to that of B-RafV600E.
(C) Effects exerted by B-Raf mutants on B-Raf-mediated stimulation of the mitogen-
activated protein kinase (MAPK) cascade. HEK293T cells expressing the indicated B-Raf
mutants were kept in serum-deprived medium (18 h) and harvested. Total cell lysates
(50 μg) were immunoblotted with the indicated phosphospeciﬁc antibodies. α-Tubulin
expression is shown for normalization. Data are representative of three different
experiments (pEF: mock-transfected cells).
Fig. 6. Evaluation of B-Raf/C-Raf heterodimer formation. (A) Demonstration of B-Raf/C-Raf heterodimerization. HEK293T cells, expressing the indicated B-Raf mutants and C-Raf
were kept in serum-deprived medium and harvested. Protein lysates (800 μg) were immunoprecipitated with an anti-B-Raf antibody and subjected to western blotting with anti-
myc and anti-C-Raf antibodies. Data are representative of two different experiments. (B) Effects exerted by co-expression of B-Raf mutants and C-Raf on the mitogen-activated
protein kinase (MAPK) cascade. HEK293T cells, expressing the indicated B-Raf mutants, and when indicated C-Raf, were kept in serum-deprived medium and harvested. Total cell
lysates (50 μg) were immunoblotted with the indicated antibodies. Data are representative of at least three different experiments (pEF: mock-transfected cells).
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results in a signiﬁcant increase of Erk phosphorylation above back-
ground. Interestingly, B-RafWT, which presents a remarkable high basal
activity when expressed alone, is not characterized by a signiﬁcant
increase of MAPK pathway activation after co-expression with C-Raf. In
order to evaluate the functional consequences of the B-Raf/C-Raf
heterodimer formation, we ﬁnally assessed the transforming potential
of the single and double B-Raf mutants in NIH-3T3 cells.
In ﬁrst instance, focus assays were performed in cells transfected
with the different B-Raf expressing constructs. As shown in Fig. 7A,
only NIH-3T3 cells transfected with the activating mutant B-RafV600E
show a signiﬁcant increase of transformation foci formation above
background (P=0.01 vs. B-RafWT). On the contrary, cells transfected
with the single mutants B-RafD594V and B-RafG596R and the double
mutants B-RafD594V+V600E and B-RafG596R+V600E were devoid of
transforming activity.
Furthermore, we evaluated the capacity of NIH-3T3 cells, stably
expressing B-RafG596R and B-RafG596R+V600E mutants, to form tumors
in NOD-SCID mice. As shown in Fig. 7B, only cells expressing the
activating mutant B-RafV600E formed fast growing tumors. On the
contrary, cell lines expressing B-RafG596R and B-RafG596R+V600E
mutants, as those transfected with the mock construct, were
completely devoid of any growing capacity in the sub-cutaneous
tissue of the immune-suppressed mice.
In summary, the obtained data conﬁrm previous ﬁndings demon-
strating the ability of B-RafG596R to heterodimerize with C-Raf and
induce its transactivation [3,15]. However, in discordance with a
previous report [15], they indicate that also kinase-impaired/dead
mutants, including B-RafG596R itself, or B-RafD594V and B-RafK-, possesthis capacity. Interestingly, for the double mutants B-RafD594V+V600E
and B-RafG596R+V600E the structural integrity necessary to allow
heterodimerization with C-Raf is demonstrated. However, more
importantly, these data indicate that conformational modiﬁcations
of the A-loop do not inﬂuence the strength of B-Raf/C-Raf hetero-
dimerization and C-Raf transactivation, providing functional evidence
that the key contact points between B-Raf and C-Raf are located
outside of the activation loop. Finally, we demonstrate that the B-Raf/
C-Raf heterodimers do not posses transforming activity in a ﬁbroblast-
derived cell lineage, at the close to physiologic concentrations
expected at least to be reached in NIH-3T3 cells transfected only
with the B-Raf expressing constructs.
4. Discussion
In the ﬁrst part of this study, we analyzed the degree of the loss of
function of B-Raf inactivating mutation G596R and the possible
molecular mechanisms involved in the phenomenon.
In HEK293T cells, kinase assays, evaluation of B-Raf-mediated
stimulation of the mitogen-activated protein kinase (MAPK) cascade
and reporter assays show a loss of function of the single inactivating
mutant B-RafG596R, and demonstrate that the G596R inactivating
mutation inserted in cis in the background of the activating mutation
V600E disrupts the constitutive active kinase function of the B-
RafV600E mutant. These experiments indicate that B-RafG596R is a
kinase-impaired mutant. In particular, this notion does not derive
only from the biochemical results obtained comparing the single
mutants, but is strongly enforced by the ﬁnding that a signiﬁcant
abrogation of the kinase function occurs in the mutant containing
Fig. 7. Transforming activity of the single and double inactivating B-Raf mutants in NIH-
3T3 cells. (A) Focus assays in NIH-3T3 cells. NIH-3T3 cells were transiently transfected
with the indicated BRAF mutants and grown in low serum for 15 days before
transformation foci counting. Experiments were performed in duplicate and data were
collected from three independent runs. Foci counts were represented as average±S.D.
⁎P=0.01 vs. BRAFWT. (B) In vivo tumorigenic activity of NIH-3T3 cells transfected with
BRAF mutants. NIH-3T3 cells stably transfected with the indicated BRAF mutants were
injected in the right ﬂank of NOD-SCID mice and volume of developing tumors was
followed for 20 days before sacriﬁcing the animals. Data are representative of three
different experiments (pEF: mock-transfected cells).
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activating amino acid substitution.
This study gave us also the possibility to test the B-Raf kinase
assay conditions. Interestingly, we found that increasing concen-
trations of ATP enhance the efﬁciency of the B-Raf kinase assay,
magnifying the difference between B-RafWT and B-RafV600E Mek
phosphorylating capacity. Thus, differences in the composition of
the kinase assay reaction might explain kinase activity differences
described for the different B-Raf mutants by different authors
[3,23]. Due to our ﬁndings, we choose to use a kinase assay reaction
mixture containing 3 mM ATP. Interestingly, this high ATP
concentration allowed to demonstrate that the G596R mutations,
although severely kinase-impaired, retain a minimal kinase activity
(Fig. 1C), not detectable at low ATP conditions (Supplementary Fig.
3) or in the D594V mutants. At variance, in the intact HEK293T
cells these mutants behave as genuine kinase-dead isoforms
(Fig. 1E and F). This discrepancy is related to the use of high
concentrations of ATP in the in vitro MEK phosphorylation assays,
which allow to rescue at least in part an impairment in the ATP
binding capacity involved in the loss of the kinase function of the
G596R mutants, as will be discussed below.While a clear explanation of the inactivity of B-RafD594V and B-
RafD594V+V600E mutants relies on the loss of the lone pair of electrons
of the side chain chelating the magnesium atom [13,14] that ensues
the substitution of D594 to valine, more complex is the disrupting
mechanism of the Arg596 mutation on the kinase functionality. In
order to unveil the molecular basis of such mechanism, we next
comparedmolecular dynamics simulations of the structural models of
the considered mutants of B-Raf. The analyses of the trajectories
yielded three signiﬁcant new ﬁndings. In ﬁrst instance, the stabiliza-
tion of the inactive conformation of B-RafG596R, resulting from the
lowering of the electrostatic energy of interaction, appears to be
unlikely the origin of the impaired catalytic activity of the enzyme
since B-RafG596R+V600E, in spite of destabilizing the inactive confor-
mation of B-Raf, still acts as kinase-impairedmutant. This was actually
unexpected, since the conformational changes affecting the activation
loop are the only events reported as necessary to activate the enzyme
[3,4], with stabilizing interactions between the activation loop and the
catalytic cleft being considered as favoring the inactive state of the
enzyme under basal conditions [3,17].
The disruption of the kinase activity in the DFG inactivating
mutants seems to depend primarily from the direct (amino acid
substitution) or indirect (sequestration by Arg596) alteration of the
catalytically important amino acid Asp594. Indeed, in second
instance, the analysis of the molecular interactions of Arg596
unveiled that this residue is increasingly implicated in the formation
of electrostatic enforced hydrogen bonds with the catalytically
important residue Asp594 during the entire course of the simulation,
either in the single or in the double mutant (Fig. 3). Since Asp594 has
a catalytically important role associated with the formation of the
magnesium binding site [13,14], the impaired activity of G596R
mutants seems to rely on an indirect effect of Arg596 on the
anchoring of ATP that occurs through the formation of a salt bridge
with the side chain of Asp594. This interaction results in the
sequestration of the latter amino acid, which looses the appropriate
spatial localization and/or conformation necessary for anchoring the
phosphate donor.
Importantly, we were able to conﬁrm this hypothesis by studying
the activity proﬁle of two additional mutants, B-RafG596E and B-
RafG596E+V600E, characterized by the substitution of Gly596 with a
glutamate residue, which has a side chain of similar size as arginine,
but cannot form the proposed salt-bridge with Asp594. The ﬁnding
that these mutants have a normal/high kinase activity conﬁrms that
the sequestration of Asp594 from its magnesium binding function is
an essential determinant of the loss of activity of the G596R mutant.
The evidence that the B-RafG596E mutant has a higher kinase activity
than wild type B-Raf might be related to a possible steric clash in the
DFG motif, due to the substitution of Gly596 with an amino acid
presenting a bigger side chain, responsible for a possible facilitation of
the kinase activity of the enzyme. Further studies are needed to clarify
this aspect.
Finally, in third instance, the molecular dynamics simulations
allowed to identify different conformations of the activation loop in
the four constructs containing either single inactivating mutations or
double inactivating/activating ones. These observations prompted us
to explore possible relationships between the conformations of the
activation loop and additional functions of B-Raf such as the
heterodimerization with C-Raf and its transactivation.
This was accomplished in the second part of the study, where we
analyzed the ability of the single and double inactivating mutants of
B-Raf to generate heterodimers with C-Raf and the possible functional
consequences of the B-Raf/C-Raf heterodimer formation, eventually
responsible for the cancer-associated phenotype described for the
inactivating mutants.
At variance with the results obtained in HEK293T cells, transient
expression of all the considered kinase-impaired B-Raf constructs in
COS-7 and NIH-3T3 cells results in some degree of activation of the
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be explained by the previously demonstrated occurrence of B-Raf/C-
Raf heterodimerization in the intact cell, resulting in C-Raf transacti-
vation and rescue of part of the B-Raf capacity to activate the MAPK
pathway, also in the presence of inactivating mutants [3,15,16].
Interestingly, this phenomenon is not detectable in HEK293T cells (Fig.
1). Thus, in order to demonstrate heterodimer formation between the
considered kinase-impaired constructs, including the B-RafK- mutant,
and C-Raf, HEK293T cell were transiently co-transfected with the
different BRAFmutants and CRAF, and either co-immunoprecipitation
of B-Raf and C-Raf or the degree of MAPK pathway activation, deriving
from the synergic action of the overexpressed Raf isoforms, were
analyzed. These experiments clearly indicate the formation of
functional B-Raf/C-Raf heterodimers in all examined cases, including
all the kinase-impaired mutants considered (B-RafK-, B-RafG596R,
B-RafG596R+V600E, B-RafD594V and B-RafD594V+V600E) and B-RafWT and
B-RafV600E, even if in these latter the measured increase of MAPK
phosphorylation induced by co-expression with C-Raf is marginal,
probably because of the already very high basal activity. Similarly, the
gain of function of B-Raf/C-Raf heterodimers could not be observed in
COS-7 cells co-expressing B-Raf and C-Raf (see Supplementary Fig. 4).
We can hypothesize that this lack of measurable activity might again
be related to a too high basal MAPK cascade activation in COS-7 cells
transfected with the B-Raf mutants which covers the marginal
additional signaling drive exerted by the overexpressed B-Raf/C-Raf
heterodimers.
The other interesting ﬁnding of this study is that B-Raf/C-Raf
heterodimerization and C-Raf transactivation might not involve the
activation loop of the enzyme as far as the similar functional behavior
shown by all mutants in the above assays does not correlate with the
results of the molecular dynamics simulations that indicate different
conformations of the activation loop in the four constructs. Thus, the
heterodimerization and transactivation activities of B-Raf may rely on
protein domains localized outside of the catalytic core. This evidence
supports the data from previous mutational and peptide arrays
experiments which localized possible heterodimerization surfaces of
B-Raf and C-Raf in regions of the kinase domain localized up-stream
and down-stream of the A-loop [16].
An open question remains the reason of the reduced capacity of
B-Raf inactivating mutants (in the absence of C-Raf over-expression)
to activate the MAPK pathway in the intact HEK293T cells at
variance with COS-7 and NIH-3T3 cells. We could exclude that this
is related to a reduced basal expression of C-Raf in HEK293T cells,
whose expression actually results evenly super imposable to that of
the other cell lines (data not shown). Further studies are necessary
to elucidate this aspect, eventually related to expression differences
of other types of proteins involved in potentiating B-Raf/C-Raf
heterodimerization or C-Raf transactivation in physiologic
conditions.
Finally, we evaluated the transforming capacity of the considered
inactivating mutants and derived B-Raf/C-Raf heterodimers. For this
purpose we performed in vitro colony assays in NIH-3T3 cells
transfected with the BRAF constructs and in vivo tumorigenic assays
in NOD-SCID mice injected subcutaneously with NIH-3T3 cells stably
expressing the G596R B-Raf mutants. In agreement with a previous
report [10], these experiments conﬁrm the functional impairment of
the single and double inactivating mutants. Moreover, they indicate
that the B-Raf/C-Raf heterodimers do not posses transforming activity
in a ﬁbroblast-derived cell lineage at the close to physiologic
concentrations expected to be reached at least in NIH-3T3 cells
transfected only with the BRAF constructs. It remains unclear whether
D594V or G596R are only “passenger” mutations simply retained by
chance during clonal expansion. Indeed, other examples of “passen-
ger” mutations in oncogenic kinases, like some mutations in FLT3 for
example, have been reported in human samples [24]. The obtained
results seem to conﬁrm this possibility. However, it cannot beexcluded that in speciﬁc cell lineages, such as i.e. colon carcinoma
cells, where the B-RafG596R mutation was initially described, their
signals through C-Raf or in a kinase-independent manner through
pathway(s) alternative to the MAPK pathway, might be important for
tumor development. Further in vivo experiments may help to clarify
this issue.Acknowledgements
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